<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621773</url>
  </required_header>
  <id_info>
    <org_study_id>2019SZ-087</org_study_id>
    <nct_id>NCT04621773</nct_id>
  </id_info>
  <brief_title>Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss</brief_title>
  <official_title>Comparing the Live Birth Rate of Preimplantation Genetic Screening Versus Spontaneous Pregnancy in Patients With Unexplained Recurrent Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY AIM: to study the pregnancy outcomes and offspring development of patient with&#xD;
      Unexplained Recurrent Pregnancy Loss Treated by PGS and spontaneous pregnancy, and to compare&#xD;
      the health economic indicators and patient satisfaction of the two modes of pregnancy, so as&#xD;
      to better guide the clinical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      400 patients with two times or more unexplained pregnancy loss, who wants to be pregnant via&#xD;
      preimplantation genetic screening procedure or spontaneous pregnancy are intended to be&#xD;
      enrolled. They are going to divided into two groups: PGS(preimplantation genetic screening)&#xD;
      group and SP(spontaneous pregnancy) group. The pregnancy outcomes and offspring development&#xD;
      of those patients will be followed up by our investigators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>2 years of following up</time_frame>
    <description>the rate of the birth of a living fetus</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Recurrent Pregnancy Loss</condition>
  <condition>Preimplantation Genetic Screening</condition>
  <arm_group>
    <arm_group_label>PGS(Preimplantation Genetic Screening)</arm_group_label>
    <description>patients with two times or more unexplained pregnancy loss, who wants to be pregnant via preimplantation genetic screening procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SP(spontaneous pregnancy )</arm_group_label>
    <description>patients with two times or more unexplained pregnancy loss, who wants to be pregnant via spontaneous pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preimplantation Genetic Screening(exposure)</intervention_name>
    <description>Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).</description>
    <arm_group_label>PGS(Preimplantation Genetic Screening)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who seek treatment in our Recurrent Pregnancy Loss clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with two times or more unexplained pregnancy loss(less than 24 weeks of&#xD;
             gestational age, biochemical pregnancy excluded), who wants to be pregnant via&#xD;
             preimplantation genetic screening procedure or spontaneous pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  anatomic abnormality of the reproductive system; endocrine metabolic disease;&#xD;
             autoimmune related disease; chromosomal abnormalities; hydrosalpinx; cervical&#xD;
             insufficiency.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rong Li, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Center of Reproductive Medicine, Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of Reproductive Medicine, Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Haidian</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Murugappan G, Shahine LK, Perfetto CO, Hickok LR, Lathi RB. Intent to treat analysis of in vitro fertilization and preimplantation genetic screening versus expectant management in patients with recurrent pregnancy loss. Hum Reprod. 2016 Aug;31(8):1668-74. doi: 10.1093/humrep/dew135. Epub 2016 Jun 7.</citation>
    <PMID>27278003</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unexplained Recurrent Pregnancy Loss</keyword>
  <keyword>Preimplantation Genetic Screening</keyword>
  <keyword>spontaneous pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

